Shigella vaccine immunity checked years later in african kids
NCT ID NCT07320716
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows up on African children who received an experimental Shigella vaccine in earlier studies. Researchers will take blood samples 1, 2, and 3 years after the last vaccine dose to see how long the immune protection lasts. No new vaccines are given in this study. The goal is to understand if the vaccine provides long-term protection against severe diarrhea caused by Shigella bacteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 528 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
26 to 55 months
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children who, as infants, previously participated in two completed studies (H06\_01TP or H06\_02TP) and were vaccinated with 3 or 2 doses of altSonflex1-2-3 or control vaccines, respectively, completed all previous vaccinations and are 12±1 months after the last altSonflex1-2-3 vaccination. * Individuals in good health as determined by medical history since last study visit and clinical judgment of the investigator. Exclusion Criteria: * Serious and significant progressive, unstable, or uncontrolled clinical condition(s). * Any confirmed or suspected immunosuppressive or immunodeficient condition. * Clinical condition(s) representing a contraindication to blood draws. * Any behavioural or cognitive impairment or psychiatric disease. * Acute disease and/or fever at the time of enrollment. * Individuals with known or suspected HIV infection or HIV-related disease, with history of an autoimmune disorder or any other known or suspected impairment/alteration of the immune system, or under immunosuppressive therapy. * Receipt of immunoglobulins and/or any blood products or plasma derivatives, during the period starting 3 months before each study visit.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diarrhoea are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.